We limit data available in the Overview Report for users who do not have Powerpack
Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Target Price Range
Recommendation Rating
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 0.68 | 0.10 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | — | 3.79 | 0.90 | — | — | — |
High Price
|
| — | — | — | — | — | — | — | 19 | 27 | 11 | — | — | — |
Employees
|
| — | — | — | — | — | 0.00 | 0.00 | 0.88 | 0.75 | 1.22 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | 12.56 | 12.56 | 16.69 | 20.31 | 13.43 | — | — | — |
Revenue
|
| — | — | — | — | — | 21.81% | 21.81% | 21.32% | 11.89% | 10.32% | — | — | — |
Gross Margin
|
| — | — | — | — | — | 1.02 | 1.02 | 1.53 | 0.04 | (1.13) | — | — | — |
EBT
|
| — | — | — | — | — | 8.13% | 8.13% | 9.14% | 0.18% | (8.40%) | — | — | — |
EBT Margin
|
| — | — | — | — | — | 0.00 | 1.00 | 1.33 | (0.03) | (1.14) | — | — | — |
Net Income
|
| — | — | — | — | — | — | 0.07 | 0.06 | 0.08 | 0.09 | — | — | — |
Depreciation
|
| — | — | — | — | — | 0.00 | 1.83 | 2.27 | 1.99 | 0.82 | — | — | — |
Revenue/Sh
|
| — | — | — | — | — | — | — | — | 0.00 | (0.07) | — | — | — |
Earnings/Sh
|
| — | — | — | — | — | — | 0.25 | (0.05) | 0.06 | (0.05) | — | — | — |
Cash Flow/Sh
|
| — | — | — | — | — | — | (0.02) | (0.01) | (0.02) | 0.00 | — | — | — |
Capex/Sh
|
| — | — | — | — | — | — | 0.24 | (0.06) | 0.04 | (0.05) | — | — | — |
Free CF/Sh
|
| — | — | — | — | — | 0.00 | 0.09 | 0.58 | 0.49 | 0.59 | — | — | — |
Book Value/Sh
|
| — | — | — | — | — | — | 6.84 | 7.37 | 10.21 | 16.35 | — | — | — |
Shares
|
| — | — | — | — | — | — | — | — | — | — | — | — | — | PE Ratio |
| — | — | — | — | — | — | — | — | — | — | — | — | — | PS Ratio |
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
PB Ratio
|
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Sales
|
| — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.47) | 5.00 | — | — | — |
EV/FCF
|
| — | — | — | — | — | — | 1.73 | (0.39) | 0.57 | (0.75) | — | — | — |
Op' Cash Flow
|
| — | — | — | — | — | — | (0.12) | (0.05) | (0.15) | (0.04) | — | — | — |
Capex
|
| — | — | — | — | — | — | 1.61 | (0.45) | 0.41 | (0.79) | — | — | — |
FCF
|
| — | — | — | — | — | 0.20 | 0.20 | 4.63 | 5.81 | 9.14 | — | — | — |
Working Cap'
|
| — | — | — | — | — | 0.10 | 0.31 | 1.45 | 1.88 | 0.94 | — | — | — |
Total Debt
|
| — | — | — | — | — | (0.42) | (0.21) | 0.83 | (1.12) | 0.72 | — | — | — |
Net Debt
|
| — | — | — | — | — | 0.59 | 0.59 | 4.25 | 4.99 | 9.58 | — | — | — |
Sh' Equity
|
| — | — | — | — | — | 0.00% | 29.30% | 19.49% | (0.30%) | (10.21%) | — | — | — |
ROA
|
| — | — | — | — | — | 395.14% | 175.61% | 19.79% | 2.11% | (6.07%) | — | — | — |
ROIC
|
| — | — | — | — | — | 0.00% | 253.80% | 54.96% | (0.59%) | (15.59%) | — | — | — |
ROE
|
Analyst Commentary (Summary)
Cellyan Biotechnology Co., Ltd (HKPD) Latest News
16 Jan
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) has successfully closed its initial public offering (IPO), raising significant capital to support its growth and expansion plans. The IPO attracted considerable investor interest, reflecting confidence in the company's business model and market potential. Proceeds from the offering will be utilized for strategic initiatives, including research and development, enhancing digital technology capabilities, and expanding market reach. This milestone marks a significant step for HKPD as it aims to strengthen its position in the pharmaceutical digital technology sector. The successful IPO is expected to provide substantial capital for strategic initiatives that could significantly enhance the company's market position and growth trajectory.
Cellyan Biotechnology Co., Ltd has received a notice from Nasdaq regarding a deficiency in its bid price, indicating that the company's stock has fallen below the minimum required bid price of $1.00 per share. The company has a 180-day grace period to regain compliance with Nasdaq's listing requirements. Failure to do so may result in delisting from the exchange, which could adversely affect its market position and investor confidence. The bid price deficiency could moderately influence investor sentiment and market performance, but the company has time to address the issue.
17 Dec
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) held its 2025 Annual Meeting of Stockholders, where key decisions regarding corporate governance and strategic direction were made. Shareholders voted on various proposals, including the election of board members and approval of financial statements. The meeting highlighted the company's commitment to transparency and shareholder engagement as it navigates future growth opportunities in the pharmaceutical digital technology sector. The outcomes of the meeting may influence operational aspects and market sentiment but are not expected to significantly alter the company's overall trajectory.
29 Nov
An insider at Hong Kong Pharma Digital Technology Holdings Limited (HKPD) increased their stake in the company over the past year, indicating potential confidence in the firm's future performance. This move may reflect the insider's belief in the company's growth prospects or upcoming developments. Insider buying can signal confidence in the company's future, potentially influencing market sentiment and performance.
15 Apr
Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) has a Return on Equity (ROE) of 36%, significantly higher than the industry average of 14% in the Logistics sector. This indicates effective profit generation from shareholder investments, with the company earning $0.36 for every dollar invested. While the company has a debt-to-equity ratio of 0.23, which is not excessive, it suggests a high-quality business. However, high ROE does not always equate to high profitability, especially if debt levels are high. Investors are advised to consider other factors, including growth potential and market conditions, before making investment decisions. The company's strong ROE indicates effective profit generation, but the impact is moderated by its debt levels and market conditions.
28 Mar
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported its financial results for the six months ending September 30, 2024. The company highlighted key performance metrics, including revenue growth and profit margins, reflecting its strategic initiatives and market positioning. Management expressed optimism about future prospects and ongoing projects aimed at enhancing operational efficiency and expanding market reach. Moderate financial performance improvements indicate potential for future growth but are balanced by existing market challenges.
23 Jan
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) has announced the pricing of its initial public offering (IPO), setting the price at a specified range. The IPO aims to raise capital to support the company's growth and expansion in the pharmaceutical digital technology sector. The offering is expected to attract significant investor interest, reflecting confidence in HKPD's business model and market potential. The IPO is a major strategic move that could significantly enhance the company's capital and market presence.
Cellyan Biotechnology Co., Ltd (HKPD) has posted strong revenue growth, surging 27% CAGR from HK$12.56 million in 2022 to HK$20.31 million in 2024, fueled by a 42% headcount expansion to support R&D scaling. However, this hyper-growth masks severe profitability erosion: gross margins plunged 45% to 11.9%, EBT cratered 98% to near-zero, and net income flipped to a HK$27,100 loss amid 38% share dilution. Revenue per employee and per share both declined, highlighting efficiency strains typical in early-stage biotechs chasing pipeline milestones.
Balance sheet resilience offers some buffer, with shareholders’ equity up 749% to HK$4.99 million and cumulative positive free cash flow of HK$1.57 million funding modest capex, though rising debt (quadrupled to HK$1.88 million) and ballooning working capital raise liquidity concerns. Trading near book value with low EV/Sales multiples suggests undervaluation for risk-tolerant investors, but zero insider activity and wide analyst price spreads underscore binary biotech risks.
Looking ahead, projections imply revenue stability and potential margin recovery to 20% could drive meaningful upside, per DCF models showing 2x intrinsic value. Yet, downside looms large—40% chance of deeper losses, trial failures, or further dilution could erode equity and heighten delisting risks in a volatile HK biotech sector. Read the full analysis for detailed Monte Carlo simulations and peer benchmarks.